Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Orange Book Blog: At the Intersection of Patent Law and FDA Law

Intellectual Property Law

: Orange Book Blog: At the Intersection of Patent Law and FDA Law

ACI "Maximizing Pharmaceutical Patent Life Cycles" Conference, New York, October 15-16

By Aaron Barkoff

American Conference Institute is holding its ninth annual "Maximizing Pharmaceutical Patent Life Cycles" conference October 15-16 in New York.  According to ACI, this "definitive Hatch-Waxman event provides the crucial information for pharmaceutical patent counsel to cultivate, modify, and enhance a foundation for their life cycle strategies."

The agenda includes many topics covered on Orange Book Blog.  Selected talks include:

• "Constructing, Adjusting, and Executing a Pharmaceutical Patent Life Cycle Management Plan"
• "View from the FTC," presented by Saralisa Brau, Health Care Services and Products Division, FTC
• "Navigating the Complexity of Structuring Patent Settlement Options Between Brand Name and Generic Pharmaceutical Companies"
• "Eye on the Bench:  Identifying Judicial Trends in Pharmaceutical Patent Cases"
• "Mastering the Intricacies of the 180-Day Generic Market Exclusivity"
• "Plotting a Course Into Safe Harbor for Branded Pharma"
• "View from the FDA," presented by Elizabeth Dickinson, Office of Chief Counsel, FDA
• "Slicing Through the Complex Spectrum of Declaratory Judgment Actions in Pharmaceutical Patent Cases"
• "Factoring the Role, Challenges, and Impact of Orange Book Listings and Delistings in Patent Portfolio Management"

In addition, two optional post-conference workshops are offered on October 17th:  a brand name master class entitled "Overpowering the Challenges in Increasing the Pharmaceutical Patent Life Cycle Through Patent Extensions" and a generics master class entitled "Adding Value to Paragraph IV Certifications and Notice Letters."

For more information or to register, please visit the conference website.

Orange Book Blog readers can save $200 by using registration code S.

Full post as published by Orange Book Blog: At the Intersection of Patent Law and FDA Law on September 21, 2008 (boomark / email).